Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Yulong Gao(The University of Queensland), Mark J. Smyth(The University of Queensland), Michele W.L. Teng(University of Queensland), Michael Hölzel(University Hospital Bonn), Christian Engwerda(QIMR Berghofer Medical Research Institute), Stephen J. Blake(QIMR Berghofer Medical Research Institute), Éric Vivier(Centre d’Immunologie de Marseille-Luminy), Jai Rautela(Walter and Eliza Hall Institute of Medical Research), Tobias Bald(QIMR Berghofer Medical Research Institute), Fernando Souza-Fonseca-Guimarães(The University of Queensland), Jason S. Lee(Queensland University of Technology), Arabella Young(The University of Queensland), Meriem Messaoudene(Centre Hospitalier de l’Université de Montréal), Shin Foong Ngiow(Parker Institute for Cancer Immunotherapy), Kyohei Nakamura(QIMR Berghofer Medical Research Institute), Gabrielle T. Belz(The University of Queensland), Susanna S. Ng(Griffith University), Kazuyoshi Takeda(Peter MacCallum Cancer Centre), Laurence Zitvogel(Inserm), Laurent Bartholin(Université Claude Bernard Lyon 1), Nicholas D. Huntington(The University of Melbourne), Jasmin Straube(QIMR Berghofer Medical Research Institute), Juming Yan(The University of Queensland), Nicola Waddell(QIMR Berghofer Medical Research Institute)
Cited by 639
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Functions of natural killer cells
|Nature Immunology|2008|3.8k
Immune surveillance of tumors
|Journal of Clinical Investigation|2007|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
TLR3 Deficiency in Patients with Herpes Simplex Encephalitis
|Science|2007|1.1k